Citi Sees 35% More in Eli Lilly After a Month of Drift
Citigroup argues Eli Lilly has 35% of upside left even as pricing pressure and a slow oral GLP-1 launch keep the stock stuck. What the math implies from the last close.
Citigroup says Eli Lilly shares have a path to 35% gains from current levels, a call that lands after a month of sideways trading and with the stock last closing at 1,183.46 on Sept. 25, 2026.
Eli Lilly and Co. (LLY) has spent the past month going nowhere in particular, and Citigroup is treating that pause as an entry point rather than a warning. The bank sees a path to 35% gains from here, according to 24/7 Wall St — a call made against a backdrop of drug pricing headwinds, an oral GLP-1 launch that has been slower out of the gate than bulls hoped, and a competitor whose shares are in freefall.
The stock itself has been quiet. Eli Lilly last closed at 1,183.46, up 0.13% on the day from a prior close of 1,181.89, having traded between 1,160.84 and 1,190.00 during the session on Sept. 25, 2026. That is a narrow band for a company of this size, and it is consistent with the description of a month spent wavering rather than trending.
What a 35% move would actually look like
Applied to the most recent close, a 35% gain is a large absolute number. On an illustrative basis — taking the last traded price and multiplying it by 1.35 — the implied level works out to roughly 1,597.67. That is arithmetic on the two figures available, not a published price target, and the actual objective Citigroup has set has not been detailed here. But it frames the scale of the call: the bank is not arguing for a modest re-rating. It is arguing that the market has mispriced a franchise whose growth runway still has years on it.
For context on the tape the stock is being measured against, the broad market closed higher the same day. The S&P 500 tracker (SPY) finished at $771.35, up 0.54%; the Nasdaq 100 tracker (QQQ) closed at $744.50, up 0.46%; and the Dow tracker (DIA) ended at $517.49, up 0.94%. Eli Lilly's 0.13% gain lagged all three, which is the practical definition of a stock that is not participating.
The three things holding the shares back
Three specific pressures are named in the bearish read, and they are different in kind.
- Pricing headwinds. This is the structural one. Obesity and diabetes drugs have become the most politically visible category in American pharmaceuticals, and the direction of negotiated and list pricing has been one way. Volume growth can absorb price concessions for a while; the question investors are asking is how long.
- A slow oral GLP-1 launch. A pill version of a GLP-1 — the drug class behind the incretin boom — is supposed to widen the addressable market well beyond patients willing to inject. A sluggish start does not invalidate that thesis, but it delays the revenue curve, and delayed revenue is exactly what compresses a high multiple.
- A rival in freefall. Competitive distress cuts both ways. A weakened competitor concedes share, which is good for Lilly. It also raises the uncomfortable possibility that the whole category is being repriced by the market, not just one company inside it.
That third point is the crux of the disagreement. If a peer's collapse reflects company-specific execution failure, Lilly's pause is a buying opportunity. If it reflects the market marking down the long-run economics of obesity drugs generally, then the pause is the early part of a longer stall.
Why the bull case survives a flat month
A month of drift is a short window in the life of a drug franchise. Launch curves for oral formulations depend on manufacturing scale-up, payer coverage decisions and prescriber habit — none of which resolve in four weeks. A bank taking a 35% view is implicitly saying the slow start is a timing problem, not a demand problem, and that pricing pressure is already reflected in a share price that has stopped going up.
Launch curves for oral formulations depend on manufacturing scale-up, payer coverage decisions and prescriber habit — none of which resolve in four weeks.
The counter-argument is that consensus on this name has been uniformly bullish for a long time, which is itself a risk. When every institutional model already assumes category dominance, there is limited room for upside surprise and considerable room for disappointment. The narrow 1,160.84–1,190.00 day range suggests neither side is forcing the issue right now.
What to watch from here
The near-term tells are specific and checkable. First, prescription trends for the oral product — weekly script data will show whether the launch is accelerating or has plateaued. Second, any formal commentary on net pricing, which determines whether volume growth is translating into revenue growth at the rate models assume. Third, the trajectory of the distressed rival: a stabilization there would support the company-specific explanation, while further deterioration would strengthen the case that the sector's economics are being reassessed wholesale.
Fourth, and most immediately, whether the stock can break out of the range it has been stuck in. A month of sideways action after a long advance is ambiguous by nature — it is the same chart pattern for consolidation before a further leg up and for distribution before a decline. Citigroup has picked a side. The next several weeks of launch data will decide whether that call looks early or wrong.
Investors weighing the name should note that a 35% target on a stock this large requires a very substantial addition of market value, and that the path to it runs entirely through the same oral launch that has so far disappointed. The upside and the risk share a single source.
Key facts
- Last close (LLY): 1,183.46, +0.13%, as of Sept. 25, 2026, 20:00 GMT
- Day range: 1,160.84 – 1,190.00; prior close 1,181.89
- Citigroup view: Path to 35% gains from current levels
- Named headwinds: Drug pricing pressure, slow oral GLP-1 launch, rival in freefall
Frequently asked questions
What is Citigroup saying about Eli Lilly?
Citigroup sees a path to 35% gains in Eli Lilly shares from current levels. The call comes after a month in which the stock wavered rather than trended, and despite acknowledged pressures including drug pricing headwinds, a slower-than-hoped oral GLP-1 launch, and a competitor whose share price is falling sharply.
Where did Eli Lilly shares last close?
Eli Lilly last closed at 1,183.46, a gain of 0.13% from the prior close of 1,181.89, with an intraday range of 1,160.84 to 1,190.00. That price is as of the last trade on Sept. 25, 2026 at 20:00 GMT. The market was closed at the time of writing.
What would a 35% gain imply for the share price?
Applying 35% to the last close of 1,183.46 gives an illustrative level of about 1,597.67. That figure is simple arithmetic on the reported close, not a published price target from Citigroup, and the bank's specific objective has not been disclosed in the available information.
What is an oral GLP-1 and why does the launch matter?
GLP-1 refers to the drug class behind modern obesity and diabetes treatments, most of which are injected. An oral, pill-form version is meant to reach patients unwilling to inject, greatly widening the market. A slow launch delays that revenue, which matters most for a stock carrying a high growth multiple.
How did Eli Lilly perform against the broader market?
On the same session, the S&P 500 tracker closed at $771.35 (+0.54%), the Nasdaq 100 tracker at $744.50 (+0.46%) and the Dow tracker at $517.49 (+0.94%). Eli Lilly's 0.13% gain trailed all three benchmarks, consistent with a stock that has stopped participating in market advances.
Is a rival's decline good news for Eli Lilly?
It cuts both ways. A weakened competitor can concede market share, which benefits Eli Lilly directly. But a sharp decline in a peer may also signal that investors are repricing the long-run economics of the entire obesity drug category, in which case Lilly's flat month could be the start of a longer stall.
